vs
Orthofix Medical Inc.（OFIX）与Regency Centers（REG）财务数据对比。点击上方公司名可切换其他公司
Regency Centers的季度营收约是Orthofix Medical Inc.的1.8倍（$404.2M vs $219.9M），Regency Centers净利率更高（50.1% vs -1.0%，领先51.1%），Regency Centers同比增速更快（8.5% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 5.4%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Regency Centers是总部位于美国佛罗里达州杰克逊维尔的房地产投资信托基金，也是以超市为核心租户的大型购物中心运营商之一。截至2020年10月21日，公司共持有415处物业，总建筑面积达5600万平方英尺，知名资产包括Serramonte Center及Village District 30%的股权。
OFIX vs REG — 直观对比
营收规模更大
REG
是对方的1.8倍
$219.9M
营收增速更快
REG
高出6.5%
2.0%
净利率更高
REG
高出51.1%
-1.0%
两年增速更快
OFIX
近两年复合增速
5.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $404.2M |
| 净利润 | $-2.2M | $202.5M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 71.0% |
| 净利率 | -1.0% | 50.1% |
| 营收同比 | 2.0% | 8.5% |
| 净利润同比 | 92.4% | 134.1% |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXREG
| Q4 25 | $219.9M | $404.2M | ||
| Q3 25 | $205.6M | $387.6M | ||
| Q2 25 | $203.1M | $380.8M | ||
| Q1 25 | $193.6M | $380.9M | ||
| Q4 24 | $215.7M | $372.5M | ||
| Q3 24 | $196.6M | $360.3M | ||
| Q2 24 | $198.6M | $357.3M | ||
| Q1 24 | $188.6M | $363.9M |
净利润OFIXREG
| Q4 25 | $-2.2M | $202.5M | ||
| Q3 25 | $-22.8M | $109.4M | ||
| Q2 25 | $-14.1M | $106.0M | ||
| Q1 25 | $-53.1M | $109.6M | ||
| Q4 24 | $-29.1M | $86.5M | ||
| Q3 24 | $-27.4M | $101.5M | ||
| Q2 24 | $-33.4M | $102.7M | ||
| Q1 24 | $-36.0M | $109.8M |
毛利率OFIXREG
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXREG
| Q4 25 | 0.2% | 71.0% | ||
| Q3 25 | -8.3% | 72.7% | ||
| Q2 25 | -7.9% | 73.8% | ||
| Q1 25 | -25.2% | 71.8% | ||
| Q4 24 | -5.3% | 71.1% | ||
| Q3 24 | -9.6% | 72.5% | ||
| Q2 24 | -12.5% | 72.3% | ||
| Q1 24 | -15.6% | 72.3% |
净利率OFIXREG
| Q4 25 | -1.0% | 50.1% | ||
| Q3 25 | -11.1% | 28.2% | ||
| Q2 25 | -6.9% | 27.8% | ||
| Q1 25 | -27.4% | 28.8% | ||
| Q4 24 | -13.5% | 23.2% | ||
| Q3 24 | -13.9% | 28.2% | ||
| Q2 24 | -16.8% | 28.7% | ||
| Q1 24 | -19.1% | 30.2% |
每股收益（稀释后）OFIXREG
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.36 | — | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | — |
| 总债务越低越好 | — | $4.7B |
| 股东权益账面价值 | $450.0M | $6.9B |
| 总资产 | $850.6M | $13.0B |
| 负债/权益比越低杠杆越低 | — | 0.69× |
8季度趋势，按日历期对齐
现金及短期投资OFIXREG
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — | ||
| Q1 24 | $27.0M | — |
总债务OFIXREG
| Q4 25 | — | $4.7B | ||
| Q3 25 | $157.2M | $4.9B | ||
| Q2 25 | $157.0M | $4.8B | ||
| Q1 25 | $156.9M | $4.6B | ||
| Q4 24 | $157.0M | $4.4B | ||
| Q3 24 | $118.5M | $4.4B | ||
| Q2 24 | $118.0M | $4.4B | ||
| Q1 24 | $118.2M | $4.4B |
股东权益OFIXREG
| Q4 25 | $450.0M | $6.9B | ||
| Q3 25 | $442.5M | $6.8B | ||
| Q2 25 | $458.3M | $6.7B | ||
| Q1 25 | $458.3M | $6.7B | ||
| Q4 24 | $503.1M | $6.7B | ||
| Q3 24 | $525.9M | $6.8B | ||
| Q2 24 | $546.0M | $6.8B | ||
| Q1 24 | $570.3M | $7.0B |
总资产OFIXREG
| Q4 25 | $850.6M | $13.0B | ||
| Q3 25 | $832.6M | $13.1B | ||
| Q2 25 | $837.2M | $12.7B | ||
| Q1 25 | $823.1M | $12.6B | ||
| Q4 24 | $893.3M | $12.4B | ||
| Q3 24 | $867.9M | $12.4B | ||
| Q2 24 | $882.0M | $12.4B | ||
| Q1 24 | $906.0M | $12.7B |
负债/权益比OFIXREG
| Q4 25 | — | 0.69× | ||
| Q3 25 | 0.36× | 0.72× | ||
| Q2 25 | 0.34× | 0.72× | ||
| Q1 25 | 0.34× | 0.69× | ||
| Q4 24 | 0.31× | 0.66× | ||
| Q3 24 | 0.23× | 0.65× | ||
| Q2 24 | 0.22× | 0.64× | ||
| Q1 24 | 0.21× | 0.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $203.9M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | 1.01× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXREG
| Q4 25 | $27.7M | $203.9M | ||
| Q3 25 | $12.4M | $218.7M | ||
| Q2 25 | $11.6M | $244.0M | ||
| Q1 25 | $-18.4M | $161.0M | ||
| Q4 24 | $23.7M | $191.4M | ||
| Q3 24 | $11.7M | $227.6M | ||
| Q2 24 | $9.0M | $203.5M | ||
| Q1 24 | $-18.6M | $167.8M |
自由现金流OFIXREG
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXREG
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXREG
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXREG
| Q4 25 | — | 1.01× | ||
| Q3 25 | — | 2.00× | ||
| Q2 25 | — | 2.30× | ||
| Q1 25 | — | 1.47× | ||
| Q4 24 | — | 2.21× | ||
| Q3 24 | — | 2.24× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
REG
| Shopping Centers | $418.0M | 103% |
| Propertymanagementservices | $4.1M | 1% |
| Assetmanagementservices | $1.7M | 0% |
